What Happened To Mercurochrome?

It was a Johns Hopkins urologist, Hugh Hampton Young, who found antiseptic properties in a mercury dye in 1918. He described it to the Journal of the American Medical Association the following year as Mercurochrome-220. The molecule behind the brand was merbromin, the disodium salt of 2,7-dibromo-4-hydroxymercurifluorescein, an organomercuric xanthene dye dispensed as a 2% solution in water or ethanol. It stained skin a carmine red lasting through repeated washing. Unlike the iodine tinctures of the period, it did not sting. Generations of parents judged the red bottle proof of care applied to a scraped knee.

In 1978 the United States Food and Drug Administration opened its review of over-the-counter drugs containing mercury. The administration did propose stripping merbromin of its generally-recognised-as-safe-and-effective status in 1982. Industry answered with silence. Reclassification followed, placing merbromin in Category II for want of evidence on safety and efficacy alike, and leaving any product still marketed over the counter misbranded. Effective on 19 October 1998, the rule ended lawful American sales without the statute ever pronouncing the word ban.

No other administration waited on fresh toxicology, none having appeared in the intervening years. Brazil halted sales in 2001, Germany in 2003 and France in 2006, with Switzerland and Canada arriving at comparable positions within a few years of one another. Iran reached the identical conclusion. Tolerance had ended among regulators for a mercury compound with no modern dossier, none of its manufacturers having filed for approval anywhere, in markets stocked with alternatives whose evidence base had thickened year on year.

Between 1971 and 1999, clinicians publishing in JAMA and the Lancet described mercury poisoning in newborns treated with merbromin for omphalocele, the abdominal-wall defect leaving viscera inside a translucent sac. Surgeons had been brushing the dye onto the sac to harden it into an eschar. Fagan and colleagues measured organ mercury in the affected infants. One neonate developed bullous skin lesions three days into therapy and died on the ninth, the child's brain and kidney tissue heavy with mercury at autopsy.

It has been established that merbromin crosses burned or otherwise permeable surfaces. The compound held bacterial growth in check, but it never killed the organism. Its carmine stain masked the reddening by which a clinician judges early infection, which made the product worse than useless on a wound turning septic. Substitution proved undramatic. Povidone-iodine and chlorhexidine gluconate took the shelf space, priced for ministries buying by the case and backed by trial evidence merbromin had not assembled across eighty years on the market.

For newborn care the World Health Organization recommends daily application of 7.1% chlorhexidine digluconate, delivering 4% chlorhexidine, to the umbilical stump through the first week of life, for babies born at home in settings recording 30 or more neonatal deaths per 1000 live births. Clean dry cord care applies elsewhere. The formulation is on the Model List of Essential Medicines for Children. Surgeons in Kinshasa have since published on 2% aqueous eosin for giant omphalocele, a low-cost substitution in the clinical niche merbromin once occupied.

Did manufacture stop anywhere outside the banning states? Trade directories list India and China as the principal origins for merbromin under CAS number 129-16-8, supplied as bulk active ingredient in fifty-kilogram lots and as finished 2% solutions in fifteen-millilitre bottles. The product circulates through Latin America and much of Asia, with a continuing presence in Eastern Europe and parts of Africa, sometimes as Mercurochrome, sometimes as mercurescein or Cinfacromin. Nail infections and laboratory staining have likely absorbed a further slice of the output.

Having entered into force on 16 August 2017, the Minamata Convention on Mercury gave the question its first binding international answer. Merbromin falls squarely inside Annex A, Part I, which lists topical antiseptics among the mercury-added products it schedules against a phase-out date of 2020. Parties number well past one hundred. Ten of them are Pacific island countries, the obligation arriving with ratification. Protection of human health is the stated purpose of the whole instrument.

What the phase-out obligation binds is manufacture, along with import and export. Use falls outside it entirely. Products in commerce inside a country on the phase-out date stay lawful to apply, as the Secretariat states plainly in its own guidance. A Party may also claim an exemption under Article 6, valid five years from the phase-out date. A bottle delivered to a provincial dispensary in 2019 therefore faces only one limit, its own shelf life. There is no duty on any pharmacist to take it away.

Article 18 obliges Parties to promote public information and education on mercury, available alternatives included. Under Article 21 they report on implementation, first full reports due in December 2021. Taken together, the pair of provisions asks governments to explain a substitution to the populations expected to live with it. The text specifies no tongue, and the budget, no line item for the sentence a grandmother in a village dispensary would need to hear spoken.

Since General Assembly resolution 37/137 of 1982, the United Nations has published a Consolidated List of Products whose Consumption or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments, its pharmaceutical volumes maintained by the World Health Organization. Criteria for inclusion date from 1985. Introducing its updates, WHO observes that governments interpret the phrase Severely Restricted very differently. Unevenness in the reporting follows, since the List holds only what administrations choose to send.

Through the Secretariat of the Pacific Regional Environment Programme, eight countries completed Minamata Initial Assessments, among them Tuvalu and Vanuatu. SPREP's waste and pollution director called one finding surprising. Despite low regional emissions, the islands retain a continued reliance on mercury-bearing products and devices, health services above all. WHO reviewed 59 such national assessments lodged up to July 2021, alongside a pair of national implementation plans. A Mercury-Free Pacific campaign set 2025 as the year the region would have been fully aware of the dangers of mercury.

How much merbromin remains on Pacific shelves is unknown. National mercury profiles inventory thermometers and dental amalgam with reasonable confidence. Topical antiseptics arrive in small consignments under general customs headings, outside essential medicines lists, sold through trade stores well away from hospital pharmacy stock. Absence of a number is not absence of a bottle. The assessments were designed for other questions. To find one would take a shelf-by-shelf audit. No ministry in the region is commissioning it.

Because one medicine dispensed on a Port Vila ward needed to inform two communities sharing it, the danger lived inside the dosage-and-administration table. A divergence between twice daily and twelve-hourly is a mis-dose, not a stylistic quibble. A numeral spelled out with no digit beside it does the identical damage. Dosage tables were handled as controlled content, units locked and digits kept alongside any spelled form. Clinician review then confirmed the warning hierarchy held its rank in the two versions. One reviewer caught a rate held over from an earlier edition, accurate once and wrong by printing.

An explanation adequate to Article 18 would say red bottle, not organomercuric salt. Naming the brand alone will not do, since Canadian and American products sold as Mercurochrome hold chlorhexidine or benzalkonium chloride instead. Neither a pharmacopoeia entry nor a customs notice would put it in those words. It would appear in Bislama and Tok Pisin across Melanesia, in Fijian and Fiji Hindi through Viti Levu, with Samoan and Tongan versions for families dispersed by migration. Speaking in the plain wording of a trade store, it would name the substitute and say why a purchase already made is worth surrendering.

Which of two accounts you accept, the evidence will not decide. Under the first, the precautionary principle did its job, withdrawing a compound of doubtful benefit at the earliest defensible moment, the lag between Washington and Apia explained by regulatory capacity, not intent. Under the second, an industry found a second life for a written-off product in jurisdictions whose inspectors number a handful. Neither account needs a villain. Look instead for the missing artefact, a sentence in the right tongue saying the red bottle is finished.